US Patent 9,662,338: Viloxazine Extended-Release Formulation Scope, Claim Analysis, and Patent Landscape

US Patent 9,662,338 protects a multipart, extended-release viloxazine formulation based on coated inert cores. Its central limitation is a three-part particle architecture: an inert core, a viloxazine-containing first layer, and an outer rate-controlling layer containing a specified release-control compound and pore former in a defined weight ratio. The patent does not broadly claim viloxazine, viloxazine hydrochloride, or every extended-release formulation. Infringement requires satisfaction of the structural, compositional, concentration, and dissolution limitations in independent claim 1.

The patent has a nominal 2034 expiration date based on the disclosed priority and filing chronology. Qelbree, Supernus Pharmaceuticals' viloxazine extended-release product, is the commercial product most directly associated with this patent family and formulation technology. The principal generic-entry risk is a formulation design-around or Paragraph IV challenge directed at the outer coating, pore-former ratio, particle architecture, or release profile.

What does US Patent 9,662,338 protect?

US 9,662,338 protects pharmaceutical formulations containing viloxazine in an extended-release coated-particle system. The independent claim requires all of the following:

Required limitation in claim 1	Scope
Inert core	A nonactive core used as the substrate
First layer	A layer containing viloxazine, optionally with an excipient
Second layer	An outer layer containing a release-rate controlling compound and a pore former
Pore former	Povidone, hypromellose, hydroxyethyl cellulose, hydroxypropyl cellulose, or an organic acid
Weight ratio	Release-rate controlling compound to pore former of 19:1 to 8.5:1.5
Release-control compound loading	5% to 65% of the extended-release component
Viloxazine content	25% to 75% of the total formulation
Release behavior	Immediate and continuous release upon administration
In-vitro release	At least 80% released over at least two hours

The claim is directed to a formulation, not a method of treating ADHD and not the viloxazine active pharmaceutical ingredient itself.

What is the protected particle architecture?

The architecture is a reservoir-type system:

An inert core forms the center.
A viloxazine-containing layer surrounds the core.
A membrane-like outer layer controls fluid penetration and drug diffusion.
The outer layer contains a pore former that modifies permeability.

The claim language requires the first and second layers to surround the core in sequence. A conventional hydrophilic matrix tablet that does not contain the claimed core-layer-shell configuration would generally fall outside the literal scope of claim 1.

What chemical materials are covered?

The release-rate controlling compound can be selected from a broad list that includes:

Ethylcellulose
Cellulose acetate
Cellulose acetate butyrate
Waxes
Hydrogenated vegetable oils
Glyceryl behenate
Glyceryl palmitostearate
PEG glyceryl esters
Poly(ethyl acrylate-co-methyl methacrylate)
Poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride)
Polyvinyl acetate
Cellulose acetate propionate
Combinations of those materials

The pore-former list is narrower. It includes povidone, hypromellose, hydroxyethyl cellulose, hydroxypropyl cellulose, and organic acids.

Claim 3 narrows the release-control compound list to ethylcellulose, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, cellulose acetate propionate, and combinations.

How do the dependent claims narrow the patent?

The dependent claims add specific formulation, dosage, and pharmacokinetic limitations.

Claim	Added limitation	Commercial relevance
2	Hydrophilic compound, including hydroxypropyl cellulose, HPMC, methyl cellulose, polyethylene oxide, povidone, alginic acid derivatives, xanthan gum, and others	Supports release modulation and coating or matrix optimization
3	Narrower release-control compound list	More limited but potentially closer to commercial coating systems
4	Release-control compound at 5% to 18% of the extended-release component	Creates a narrower concentration-based claim
5	Extended-release component consists of multiple particles	Covers multiparticulate formulations
6	Once-daily administration	Aligns with a once-daily commercial dosing model
7	Twice-daily administration	Preserves coverage for divided dosing
8	10 mg to 800 mg viloxazine	Broad dosage range
9	Viloxazine hydrochloride	Covers the salt used in the marketed product
10	Immediate-release component combined with the extended-release component	Covers IR/XR combination products
11	Cmax between 50% and 125% of IR viloxazine administered TID or BID	Pharmacokinetic product-performance limitation
12	AUC over a 24-hour interval between 80% and 125% of IR viloxazine TID or BID	Bioequivalence-style exposure limitation
13	Tablets, capsules, beads, granules, powders, caplets, troches, sachets, pouches, and sprinkles	Broadens dosage-form coverage
14	At least two extended-release components, each with its own release rate	Covers multipart release profiles and staged delivery

Claims 11 and 12 are particularly relevant to product development and generic litigation because they introduce pharmacokinetic limitations. A competing product could satisfy the structural limitations but avoid a dependent claim if its steady-state Cmax or AUC falls outside the stated ranges.

How broad is independent claim 1?

Claim 1 is chemically broad but structurally narrow.

Its chemical breadth comes from the extensive list of release-control compounds and the broad viloxazine concentration range of 25% to 75% of the total formulation. Its structural narrowness comes from the required inert core, viloxazine layer, outer coating, pore former, ratio range, and dissolution performance.

A product generally must satisfy each limitation for literal infringement. The most consequential limitations are:

The presence of an inert core.
Viloxazine in a layer surrounding that core.
A separate outer layer containing both a release-control compound and a pore former.
A release-control compound-to-pore-former ratio from 19:1 to 8.5:1.5.
Release-control compound loading of 5% to 65% of the extended-release component.
At least 80% viloxazine release over at least two hours in vitro.

The claim is less likely to capture a product using a monolithic matrix, osmotic pump, lipid matrix, or entirely different coating architecture unless the product also contains the claimed layered particle structure.

What formulations are protected by the patent?

The patent protects several formulation configurations through the dependent claims.

Multiparticulate extended-release capsules

Claims 5 and 13 cover formulations containing extended-release particles in capsules, beads, granules, powders, or sprinkles. This is commercially important because multiparticulate systems can be filled into capsules or compressed into tablets.

Once-daily viloxazine formulations

Claim 6 covers once-daily administration. Qelbree is labeled for once-daily administration in pediatric and adult patients, subject to dose titration and clinical use requirements. The claim does not itself establish clinical efficacy. It protects a formulation intended for that dosing frequency when the underlying claim 1 limitations are satisfied.

Immediate-release and extended-release combinations

Claim 10 covers a formulation that combines an IR component with the claimed XR component. This configuration can provide an early concentration increase followed by sustained exposure.

Multiple release rates

Claim 14 covers at least two extended-release components, each having its own release rate. This could include bead populations with different coating thicknesses, distinct release-control materials, or different pore-former concentrations.

The claim does not require every particle population to have the same release profile. Claim 14 instead recognizes a formulation containing separate XR components with individualized release behavior.

What is the significance of the release-control compound and pore-former ratio?

The ratio limitation is a central validity and infringement issue. Claim 1 requires the release-rate controlling compound and pore former to be present at a ratio from 19:1 to 8.5:1.5.

Expressed numerically, the permissible ratio range is approximately:

Stated ratio	Release-control compound fraction of the pair
19:1	95.0%
8.5:1.5	85.0%

This range creates a meaningful formulation design variable. A generic developer could attempt to avoid literal infringement by:

Increasing the pore-former fraction above the claimed range.
Reducing the pore-former fraction below the claimed range.
Using a pore former outside the enumerated group.
Using a release-control material outside the listed group.
Separating the pore former from the release-control layer.
Using a matrix system rather than a coated reservoir particle.

The calculation must be based on the claim's relevant weight components. Product-by-process evidence, batch records, formulation development documents, coating composition, and analytical testing would likely be important in litigation.

When does US Patent 9,662,338 lose exclusivity?

The patent has a nominal expiration date of February 14, 2034, based on the patent's priority and nonprovisional filing chronology. The effective date must be determined from the USPTO patent-term calculation, including any patent-term adjustment, terminal disclaimer, or other term modification recorded for the patent.

Event	Date or status
Earliest disclosed priority	February 14, 2013
Patent grant	May 30, 2017
Nominal 20-year term basis	February 14, 2034
Commercial product associated with the technology	Qelbree
Active-ingredient exclusivity	Separate from patent term
Generic entry	Potentially before patent expiration if a successful challenge or authorized settlement occurs

The patent term is separate from FDA regulatory exclusivity. Qelbree received FDA approval in 2021 under NDA 211964. Any five-year NCE exclusivity associated with the approval would have expired before the patent's nominal expiration date. The remaining commercial barrier is therefore primarily patent-based rather than NCE-exclusivity-based.

What is the Orange Book status of US 9,662,338?

US 9,662,338 has been associated with the Qelbree extended-release product and its formulation protection. Orange Book listing analysis must distinguish between:

A patent claiming the active ingredient.
A patent claiming a formulation.
A patent claiming a method of use.
A patent claiming a drug-delivery system.
A patent listed against a specific NDA strength or dosage form.

US 9,662,338 is a formulation patent. Its relevance to an ANDA depends on whether the proposed generic uses a formulation that falls within the listed claims and whether the applicant submits a Paragraph IV certification.

A Paragraph IV certification would assert that the patent is invalid, unenforceable, or not infringed. Under the Hatch-Waxman framework, the patent holder may file an infringement action within 45 days of receiving notice, potentially triggering a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).

Which companies are challenging the patent?

A reliable determination of current Paragraph IV challengers requires review of the latest FDA Orange Book records, ANDA notices, and federal court dockets. The patent itself does not identify later generic applicants or litigation outcomes.

The relevant litigation questions are:

Whether an ANDA applicant made a Paragraph IV certification to US 9,662,338.
Whether Supernus filed an action within the statutory 45-day period.
Whether the case concerns only US 9,662,338 or also continuation patents.
Whether the parties entered a settlement with a licensed or otherwise authorized launch date.
Whether the court issued a claim-construction, summary-judgment, or validity decision.

No litigation result should be inferred solely from the Orange Book listing. Listing establishes patent association with the approved product, not infringement, validity, or the timing of generic entry.

What patent litigation issues are most likely?

Infringement disputes

The principal infringement disputes would concern claim construction and formulation testing:

Whether a bead or pellet contains an "inert core."
Whether the viloxazine is in a distinct layer surrounding the core.
Whether the outer coating is a separate second layer.
Whether a listed compound functions as the release-rate controlling compound.
Whether an organic acid qualifies as the pore former.
How the ratio is calculated.
Whether the 80% release requirement is satisfied under the specified in-vitro method.

Validity disputes

Potential validity attacks would focus on:

Anticipation by earlier viloxazine formulations.
Obviousness based on coated-particle extended-release systems.
Written-description support for the breadth of the material lists.
Enablement across the full 25% to 75% viloxazine range and the broad release-control compound list.
Definiteness of "immediately and continuously" released.
Definiteness and reproducibility of the in-vitro release limitation.

The release-performance language can create both infringement and validity issues. If the test conditions are not sufficiently defined in the intrinsic record, the parties may dispute whether the limitation is objectively measurable.

How strong is the patent estate for viloxazine extended release?

US 9,662,338 is commercially meaningful because it combines composition, particle architecture, coating chemistry, dosage range, administration frequency, and release performance in one claim set. Its strength is highest against products that closely replicate the coated multiparticulate design.

Factor	Assessment
Product-specific relevance	High for Qelbree-like coated multiparticulate formulations
Chemical breadth	Moderate to high
Structural breadth	Moderate to low
Design-around exposure	Meaningful
Dosage-form coverage	Broad through claim 13
Pharmacokinetic coverage	Narrower but commercially relevant
Method-of-use protection	Not the primary subject of this patent
Manufacturing protection	Indirect; the patent protects the formulation rather than a manufacturing process
Generic challenge risk	Material, because the core claim contains multiple measurable limitations

The patent is stronger as a barrier against close formulation replication than as a universal barrier to viloxazine generic entry.

What manufacturing and intellectual-property barriers exist?

A generic developer must solve more than the active ingredient. The formulation presents several manufacturing requirements:

Uniform coating of inert cores.
Consistent deposition of the viloxazine layer.
Reproducible application of the outer release-control layer.
Tight control of the polymer-to-pore-former ratio.
Uniform viloxazine loading.
Consistent dissolution across batches.
Stable performance after capsule filling, tableting, or other dosage-form processing.

These requirements can create trade-secret and process-development barriers even where the patent claims are designed around the finished formulation. The patent does not necessarily prevent every alternative manufacturing process, but a process that produces the claimed formulation may still create product infringement exposure.

How can a generic product design around US 9,662,338?

Potential design-around strategies include:

Design-around strategy	Principal patent limitation targeted
Hydrophilic matrix tablet	Avoids layered inert-core architecture
Osmotic delivery system	Avoids coated-particle release mechanism
Lipid or wax matrix without the claimed layered structure	Avoids first-layer/second-layer sequence
Alternative pore former	Avoids enumerated pore-former requirement
Ratio outside 19:1 to 8.5:1.5	Avoids the claimed coating composition range
Release-control material outside the listed groups	Avoids the claimed material list
Release profile below the claimed threshold	Targets the 80% release limitation
Different viloxazine loading	Targets the 25% to 75% total-formulation limitation
IR-only or non-XR product	Avoids the extended-release requirement

A design-around may still encounter other patents in the viloxazine estate. Avoiding US 9,662,338 does not establish freedom to operate against continuation patents, method-of-use patents, or separate formulation patents.

How does US 9,662,338 compare with method-of-use and formulation patents?

US 9,662,338 is principally a formulation patent. It differs from:

Active-ingredient patents, which protect the chemical entity or salt.
Method-of-use patents, which protect treatment of ADHD or other conditions.
Dosing patents, which may cover titration, patient populations, or administration schedules.
Manufacturing patents, which protect coating, granulation, layering, or encapsulation processes.
Later continuation patents, which may pursue narrower or differently categorized claims.

For generic applicants, the full patent landscape must be evaluated patent-by-patent. A successful challenge to US 9,662,338 may not eliminate all patent barriers to an ANDA or 505(b)(2) product.

What is the revenue exposure from this patent?

The economic exposure is tied to Qelbree's extended-release viloxazine sales and the timing of generic entry. The patent can delay a close formulation competitor until its nominal 2034 expiration unless:

A generic prevails in litigation.
The patent is disclaimed or expires earlier.
The applicant enters a settlement permitting an earlier launch.
A noninfringing product reaches the market under an alternative formulation.
A regulatory pathway avoids the listed patent claims.

US 9,662,338 is unlikely to prevent all future viloxazine competition if alternative delivery systems are technically and regulatorily feasible. It is more likely to protect the commercial formulation platform used by the approved extended-release product.

Key Takeaways

US 9,662,338 is a formulation patent for layered, extended-release viloxazine particles.
Claim 1 requires an inert core, viloxazine-containing first layer, and outer release-control layer.
The outer layer must contain a listed release-control compound and listed pore former in a 19:1 to 8.5:1.5 ratio.
Viloxazine must comprise 25% to 75% of the total formulation.
At least 80% of viloxazine must be released in vitro over at least two hours.
Dependent claims cover hydrophilic excipients, multiparticulates, once- or twice-daily dosing, viloxazine hydrochloride, IR/XR combinations, broad dosage forms, and multiple release rates.
The patent is strongest against a Qelbree-like coated multiparticulate product.
Matrix, osmotic, lipid, and other non-layered systems have stronger design-around potential.
The nominal patent expiration is February 14, 2034, subject to the USPTO term record.
Paragraph IV litigation would likely focus on the layer architecture, ratio calculation, material identity, dissolution testing, and claim validity.
The patent does not by itself block every viloxazine product or every alternative extended-release technology.

FAQs

Does US 9,662,338 cover viloxazine hydrochloride?

Yes. Dependent claim 9 expressly covers formulations in which the viloxazine comprises viloxazine hydrochloride. Claim 1 also covers viloxazine formulations more generally.

Does the patent cover Qelbree capsules?

The patent is directed to the type of extended-release viloxazine formulation associated with Qelbree and covers capsules through claim 13 when the formulation satisfies the structural and release limitations.

Can a generic use the same viloxazine hydrochloride active ingredient?

Yes. The patent does not provide exclusive rights to all viloxazine hydrochloride. A generic may use the same active ingredient but must avoid infringement of the formulation and other applicable patents.

Does a formulation outside the claimed pore-former ratio avoid infringement?

It may avoid literal infringement of claim 1 if the formulation genuinely falls outside the claimed ratio and does not satisfy the limitation under an applicable doctrine-of-equivalents theory. The complete patent estate must still be reviewed.

Is the patent a method-of-treatment patent?

No. US 9,662,338 primarily claims pharmaceutical formulations. Claims 6 and 7 describe once-daily and twice-daily administration, but the patent's central protection is the formulation architecture and release profile.

References

Supernus Pharmaceuticals, Inc. (2017). Pharmaceutical compositions of viloxazine (U.S. Patent No. 9,662,338 B2). United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2021). Qelbree (viloxazine) extended-release capsules: Prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
United States Congress. (2024). Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355. United States Code.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-001	Apr 2, 2021		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-002	Apr 2, 2021		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-003	Apr 2, 2021		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013217013	⤷ Start Trial
Australia	2017206245	⤷ Start Trial
Australia	2019216707	⤷ Start Trial
Australia	2020233746	⤷ Start Trial
Canada	2864088	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,662,338

Which drugs does patent 9,662,338 protect, and when does it expire?

Summary for Patent: 9,662,338